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Objective: Ovarian cancer comprises several subtypes with widely differing levels of 21 
survival. We aimed to explore international variation in survival for each subtype to 22 
help interpret international differences in survival from all ovarian cancers combined. 23 
We also examined differences in stage-specific survival.  24 
 25 
Methods: The CONCORD programme is the largest population-based study of 26 
global trends in cancer survival, including data from 60 countries for 695,932 women 27 
(aged 15-99 years) diagnosed with ovarian cancer during 1995 to 2009. We defined 28 
six morphological groups: type I epithelial, type II epithelial, germ cell, sex cord-29 
stromal, other specific non-epithelial and non-specific morphology, and estimated 30 
age-standardised 5-year net survival for each country by morphological group. We 31 
also analysed data from 64 cancer registries for 233,659 women diagnosed from 32 
2001 to 2009, for whom information on stage at diagnosis was available. We 33 
estimated age-standardised 5-year net survival by stage at diagnosis (localised or 34 
advanced).  35 
 36 
Results: Survival from type I epithelial ovarian tumours for women diagnosed during 37 
2005-09 ranged from 40 to 70%. Survival from type II epithelial tumours was much 38 
lower (20-45%). Survival from germ cell tumours was higher than that of type II 39 
epithelial tumours, but also varied widely between countries. Survival for sex-cord 40 
stromal tumours was higher than for the five other subtypes. Survival from localised 41 




Conclusions: Given the wide variation in survival between morphological groups. 44 
Stage at diagnosis remains an important factor in ovarian cancer survival, 45 
international comparisons of ovarian cancer survival should incorporate morphology.  46 
 47 




The CONCORD-2 study, a comprehensive study on cancer survival, showed wide 50 
variation in 5-year net survival for ovarian cancer among over 779,000 women 51 
diagnosed in 61 countries(1). Age-standardised survival from ovarian cancer for all 52 
morphological subtypes combined was around 30-40% in most countries from 1995 53 
to 2009, but it varied widely between countries. Most international comparisons of 54 
ovarian cancer survival include all morphological subtypes combined(1-3). The 55 
different morphological groups have unique molecular pathways and treatment, and 56 
survival also differs widely, especially for type I and type II epithelial tumours(4-7). 57 
We have examined patterns of survival for each distinct morphological group in order 58 
to gain a better understanding of international differences in ovarian cancer survival. 59 
 60 
Type I epithelial tumours include low-grade serous, endometrioid, clear cell, 61 
mucinous and transitional cell (Brenner) carcinomas, while type II epithelial tumours 62 
include high-grade serous, undifferentiated carcinoma and malignant mixed 63 
mesodermal tumours (carcinosarcoma). Type II epithelial tumours account for 64 
approximately 70% of all malignant ovarian tumours, while only 22% of ovarian 65 
tumours are type I epithelial. Type I epithelial tumours often present at an early stage 66 
and have better prognosis than Type II epithelial tumours, which typically present at 67 
an advanced stage(4). Germ cell and sex cord-stromal tumours are rarer types of 68 
ovarian cancer, but they generally have much better prognosis than type II epithelial 69 
tumours.  70 
 71 
Stage at diagnosis also affects survival. Though most women are diagnosed at an 72 
advanced stage, stage-specific survival also differs widely between countries(2). In a 73 
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comparison of one-year net survival between six high-income countries, Denmark 74 
had the highest percentage of women with advanced disease and the second lowest 75 
survival for all stages combined(2). Thus, the international variation in ovarian cancer 76 
survival may be partially explained by the distribution of stage at diagnosis.  77 
 78 
The CONCORD-2 study on the global surveillance of cancer survival has shown the 79 
extent to which ovarian cancer survival for all morphological groups combined varies 80 
worldwide(1). However, it remains unclear how much of the variation in ovarian 81 
cancer survival could be attributed to international variation in survival for each 82 
morphological group. We aimed to examine survival from ovarian cancer by 83 
morphological group and stage at diagnosis in order to improve understanding of 84 
international differences in ovarian cancer survival. 85 
 86 
Material and methods 87 
The CONCORD-2 study was based on data for over 25.7 million patients diagnosed 88 
with one of 10 cancers, contributed by 279 population-based cancer registries in 67 89 
countries. The data included over 779,000 women diagnosed with ovarian cancer in 90 
61 countries during the 15-year period of 1995 to 2009(1). The CONCORD-2 91 
protocol, ethical approvals and quality control procedures have been described(1).  92 
 93 
We analysed data for women (aged 15-99 years) diagnosed during 1995 to 2009 94 
with a cancer of the ovary, fallopian tube, uterine ligaments and adnexa, other 95 
specified and unspecified female genital organs, peritoneum and retroperitoneum 96 
(International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) 97 
topography codes C56.9, C57.0-C57.4, C57.7-C57.9, C48.0-C48.2)(8). Recent 98 
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evidence suggests that high-grade serous carcinoma, the most common type of 99 
ovarian cancer, originates in the fallopian tube. Therefore, cancers of the fallopian 100 
tube were included in a broader definition of ovarian cancer(4). Similarly, primary 101 
peritoneal malignancies are managed in the same way as advanced-stage epithelial 102 
ovarian cancer, and they are also included(4). Tumours of the uterine ligaments and 103 
adnexa, other specified and unspecified female genital organs and retroperitoneum 104 
were included because of the close proximity of these sites to the ovaries, fallopian 105 
tubes and peritoneum. Follow-up until 31 December 2009 for vital status was 106 
available. Women diagnosed with ovarian cancer as a second or higher-order 107 
primary tumour are included in the analysis, in addition to those for whom ovarian 108 
cancer was their first cancer. Women whose cancer registration was from a death 109 
certificate or autopsy only were excluded, because their true survival time was 110 
unknown.  111 
 112 
In ICD-O-2, some borderline tumours were coded as malignant, or with a behaviour 113 
code of 3. The behaviour code changed, however, from malignant (behaviour code 114 
of 3) to not malignant or of borderline malignancy (behaviour code of 0 or 1) in ICD-115 
O-3. Due to this change in coding, some women diagnosed with borderline tumours 116 
were included in the data submissions. ICD-O-3 morphology codes were checked to 117 
detect borderline tumours that are now coded with behaviour codes of 0 or 1, and 118 
these tumours were then excluded from analysis because their inclusion would 119 
inflate survival estimates.  120 
 121 
We defined six morphological groups based on ICD-O-3 codes, literature(9) and 122 
clinical advice: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other 123 
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specific non-epithelial and non-specific morphology [Table 1]. Clear cell, 124 
endometrioid, mucinous, squamous and transitional cell (Brenner) carcinomas were 125 
classified as type I epithelial. Serous, mixed epithelial-stromal and undifferentiated or 126 
other classified epithelial carcinomas were grouped as type II epithelial. Tumours 127 
with a non-specific morphology code (8000-8004) were analysed separately. 128 
Survival for tumours with unknown morphology (0.1% of cases) is not reported. We 129 
included in the analysis all microscopically verified tumours. We also included 130 
tumours that were reported as not microscopically verified but for which we had a 131 
specific ICD-O-3 morphology code (any valid ICD-O-3 code except 8000-8004).  132 
 133 
Information on stage at diagnosis was available only from 2001; therefore, the stage-134 
specific analysis only includes patients diagnosed between 2001 and 2009. Stage at 135 
diagnosis was categorised into localised or advanced. Registries submitted stage 136 
data coded to one of several classifications: UICC Tumour-Node-Metastasis (TNM) 137 
staging system (7th edition), the Fédération Internationale de Gynécologie et 138 
d’Obstétrique (FIGO) system or SEER Summary Stage 2000. We received data on 139 
pathological and/or clinical T, N and M, as well as tumour size (in millimetres) and 140 
the number of positive lymph nodes. These data were used to create a final stage at 141 
diagnosis variable, prioritising pathological TNM information, supplemented with 142 
clinical TNM information where missing. Information on FIGO stage and SEER 143 
Summary Stage 2000 was used to supplement missing TNM information when both 144 
pathological and clinical TNM were missing, and if no data on tumour size or number 145 
of positive lymph nodes were available. TNM Stage I tumours are confined to the 146 
ovaries at diagnosis; and were defined as localised in these analyses. Stage II 147 
tumours are usually confined to the ovaries, but were defined as advanced in these 148 
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analyses. Stage III tumours have spread to regional lymph nodes and Stage IV 149 
tumours have metastasised to other organs. TNM Stage III and Stage IV tumours 150 
were defined as advanced. Where there was no information available on stage, we 151 
classified the tumours as of unknown stage at diagnosis.   152 
 153 
We analysed survival by morphological group in each country. We analysed survival 154 
by stage at diagnosis in each country, and where possible, for each registry, 155 
separately from the analysis by morphological group. Only countries with at least 10 156 
women for a given morphological group for all years combined were included in the 157 
analysis for that morphological group. For the stage-specific analysis, we included 158 
registries with at least 10 women available for analysis in each stage for any given 159 
time period. If more than 30% of tumours were unknown stage at diagnosis for a 160 
given registry during 2004-2009, then that registry was excluded from the stage-161 
specific analysis. If fewer than 10 women were available for analysis in a given 162 
registry, then the registry was excluded from the analysis by stage at diagnosis. 163 
Registries for which net survival estimates were considered as less reliable in the 164 
main CONCORD-2 analysis(1) were also excluded. Country-level survival estimates 165 
were derived by pooling data for registries that were included in the registry-specific 166 
analysis by stage at diagnosis. We only included data from countries that were 167 
included in the analysis of specific morphological groups in the analysis for non-168 
specific morphology, given that there were at least 10 women with non-specific 169 
tumours available for all years combined. If fewer than 50 women were available for 170 
survival analysis by morphological group or stage at diagnosis in a given calendar 171 




Net survival is defined as the probability of survival for cancer patients up to a given 174 
point in time after diagnosis (for example, 5 years) if death from cancer were to be 175 
the only cause of death. Net survival controls for the background mortality of 176 
competing causes of death in a population. We used the Pohar Perme estimator of 177 
net survival(10), which allows for the fact that competing risks of death increase with 178 
age. The Pohar Perme estimator was implemented using stns(11) in Stata version 179 
14(12). 180 
 181 
Net survival is reported for each country and morphological group, and separately for 182 
each registry and each stage at diagnosis. Survival by morphological group was 183 
estimated for women diagnosed during 1995-1999, 2000-2004 and 2005-2009. The 184 
cohort approach was used for women diagnosed during 1995-1999 and 2000-2004, 185 
because five or more years of follow-up were available for all patients, while a period 186 
approach was used for 2005-2009. Stage-specific survival was estimated with a 187 
cohort approach for 2001-03 and a complete approach was used for 2004-2009. 188 
 189 
Survival estimates for all ages combined were age-standardised, where possible, 190 
with the International Cancer Standard Survival (ICSS) weights(13). Age at diagnosis 191 
was categorised into five age groups: 15-44, 45-54, 55-64, 65-74 and 75-99 years. If 192 
an age-specific estimate could not be produced, or fewer than 10 women were 193 
available for analysis in an age group, data for adjacent age groups were pooled and 194 
the re-estimated survival used for both of the original age groups. If two or more age-195 
specific estimates could not be produced, fewer than 10 women were available for 196 





Data for a total of 695,932 women were available for analysis of survival by 200 
morphological group [appendix Figure 1], including 98.3% with a specific 201 
morphology, 1.6% with non-specific morphology and 0.1% with unknown morphology 202 
[Table 2]. Survival by morphological group was estimated for all stages combined. 203 
Most women were diagnosed with Type II epithelial tumours. The mean age at 204 
diagnosis varied between morphological subtype, ranging from 36 years for germ 205 
cell tumours to 66 years for tumours of non-specific morphology.  206 
 207 
Net survival for women diagnosed with type I epithelial tumours five years after 208 
diagnosis was fairly high, generally 50-60% [Figure 1]. During 2005 to 2009, age-209 
standardised 5-year survival for type I epithelial tumours varied widely, with the 210 
highest survival in Hong Kong (82.9%, 72.4-93.4%) and the lowest in Argentina 211 
(30.8%, 16.3-45.2%) [appendix Table 1]. Age-standardised survival from type I 212 
epithelial tumours also varied within each continent and over time. The between-213 
country variation in survival was widest in Central and South America (from 30.8%, 214 
16.3-45.2% in Argentina to 77.1%, 64.7-89.6% in Colombia) for women diagnosed 215 
during 2004-2009. Age-standardised net survival from type I tumours increased over 216 
time in all countries in Central and South America and North America for which data 217 
were available. In Asia, Europe, and Oceania, most countries saw an improvement 218 
in survival from type I tumours, but survival actually fell over time for some countries 219 
in these regions (from 65.5%, 59.0-72.1% to 60.8%, 50.7-70.8% in Korea and from 220 
60.3%, 49.8-70.7% to 56.9%, 42.6-71.3% in Turkey (Izmir)) [appendix Table 1].  221 
 222 
Survival from type II epithelial tumours five years after diagnosis was lower than that 223 
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of type I epithelial tumours, around only 20-45% [Figure 1]. For women diagnosed 224 
between 2005 and 2009, the highest age-standardised survival was seen in Hong 225 
Kong (61.5%, 54.8-68.2%), compared with only 18.1% (6.3-29.9%) for women in 226 
Chile (Los Rios). Age-standardised survival from type II epithelial tumours increased 227 
over time for most countries worldwide, though there were decreases in some 228 
countries. In Cuba, for example, survival was 53.4% (45.1-61.7%) for women 229 
diagnosed during 1995-99, but only 39.2% (29.3-49.1%) during 2005-2009 [appendix 230 
Table 1]. Between-country variation was widest in Central and South America, where 231 
age-standardised 5-year survival was only 18.1% (6.3-29.9%) in Chile (Los Rios), 232 
but 55.0% (44.6-65.5%) in Ecuador (Quito). Type II epithelial was the only 233 
morphological group for which survival estimates could be produced for all five 234 
African countries, but all of these estimates were not age standardised.  235 
 236 
Survival from germ cell tumours could only be presented for all women diagnosed 237 
between 1995 and 2009, because these tumours are so uncommon. As a result, 238 
most survival estimates for germ cell tumours were not age standardised. This is 239 
because younger women have the highest incidence of germ cell tumours and this 240 
subtype is extremely rare in older women. Therefore, only for a few countries were 241 
enough women available in each age group to allow for age standardisation. 242 
Considering the age-standardised estimates, the highest was in Australia (76.0%, 243 
57.6-94.5%) and the lowest in China (41.5%, 23.6-59.4%) [Figure 2; appendix Table 244 
1].  245 
 246 
Sex cord-stromal tumours are also rare, and survival could only be estimated in 11 247 
countries for all three calendar periods. During 2005-2009, net survival was over 248 
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90% at 5 years after diagnosis in Korea (100.0%, 96.0-100.0%, n=207 women) and 249 
Portugal (94.1%, 83.3-100.0%, n=64 women). However, survival varied widely 250 
between countries, and the lowest survival was almost half that seen in Korea 251 
(Japan, 58.9%, 34.2-83.7%, n=63 women). Over time, survival from sex cord-stromal 252 
tumours remained either stable, or increased, in most countries [Figure 2; appendix 253 
Table 1].  254 
 255 
Survival from other specific non-epithelial tumours was generally around 40% and 256 
slightly higher than that of type II epithelial tumours. The variation in survival was 257 
wide, ranging from only 0.3% (0.0-0.8%) in Bulgaria to 60.0% (48.4-71.5%) in Cuba 258 
[Figure 2; appendix Table 1].   259 
 260 
Age-standardised net survival for tumours of non-specific morphology was generally 261 
lower than, that of tumours with specific morphology, with a few notable exceptions 262 
[appendix Table 2].  263 
Data for 233,659 women were available from 67 registries in 25 countries for 264 
analysis of survival by stage [appendix Figure 2]. Survival by stage at diagnosis was 265 
estimated for all ovarian cancer morphologies combined. Only two Central and South 266 
American registries provided enough information on stage at diagnosis to be 267 
included in the analysis. In North America, one Canadian registry and 36 US 268 
registries provided adequate stage data. In Asia and Europe, only 12 and 13 269 
registries, respectively, provided adequate stage data for inclusion in survival 270 
analyses. No data from African registries were available for analysis by stage at 271 




Overall, 38,033 (16.3%) of these 233,659 women were diagnosed with localised 274 
ovarian cancer, 169,033 (72.3%) with advanced disease and 26,593 (11.4%) with 275 
unknown stage at diagnosis. The overall mean age was 64 years. Women 276 
diagnosed with localised ovarian cancer were the youngest (mean age 56 years), 277 
while women with an unknown stage at diagnosis were the oldest (mean age 68 278 
years). The mean age at diagnoses for women diagnosed with advanced disease 279 
was 65 years.  280 
 281 
Overall, 5-year age-standardised net survival for localised ovarian cancer (around 282 
80%) was much higher than that for advanced (around 30%) and unknown stages 283 
(around 30%) [Figure 3]. For women diagnosed with localised ovarian cancer during 284 
2004-2009, survival was much higher than for women diagnosed with advanced 285 
disease everywhere. In some countries, 5-year age-standardised survival was over 286 
90% for localised tumours, with the highest survival in Hong Kong (95.5%, 89.4-287 
100.0%). The lowest age-standardised survival from localised tumours was seen in 288 
Mississippi (US) (68.3%, 52.3-84.4%), however, this is still much higher than the 289 
highest survival for advanced-stage tumours during the same time period [appendix 290 
Table 3].  291 
 292 
For advanced-stage ovarian cancer, survival was generally around 30% [Figure 3]. 293 
Age-standardised survival from advanced-stage disease diagnosed during 2004 to 294 
2009 was highest in Tochigi, Japan (39.3%, 22.1-56.5%), while the lowest survival 295 
was in Manitoba, Canada (15.4%, 9.0-21.7%). The between-registry variation in 296 
survival for advanced-stage disease was not as wide as that of localised disease 297 




Survival from tumours of unknown stage at diagnosis was similar to or lower than 300 
that of advanced disease in most registries in Central and South America and North 301 
America during 2005-2009. For a few registries, survival from tumours of unknown 302 
stage was higher than that for advanced disease. In North America, survival from 303 
tumours of unknown stage at diagnosis was 43.7% (95% CI: 39.2-48.2) in Texas but 304 
only 31.3% (95% CI: 29.6-33.0%) for advanced-stage tumours. In Florida and 305 
Mississippi, survival for tumours of unknown stage was higher than that of advanced-306 
stage disease. In contrast to other regions, age-standardised survival from tumours 307 
of unknown stage was higher than for advanced stage disease in all Asian, 308 
European and Oceanic registries [appendix Table 3].  309 
 310 
Discussion 311 
There are few international comparisons of survival for the various morphological 312 
subtypes of ovarian cancer. The results from this large study show the importance of 313 
morphology in comparisons of survival from ovarian cancer between countries.  314 
 315 
The distribution of morphological groups may explain some of the wide international 316 
variation in survival. In Asia, for example, type I epithelial tumours are more common 317 
than in other regions, is in part due to a higher percentage of clear cell tumours. 318 
Because survival for type I epithelial tumours is generally higher than that of type II 319 
epithelial tumours, we would expect survival for all morphological groups combined 320 
to be higher in Asian countries with this larger proportion of more favourable 321 
tumours. As shown in the results, survival for all morphologies combined was 322 
generally higher in Asian countries than other regions. It is therefore important to 323 
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examine survival from ovarian cancer for each morphological group separately, at 324 
least in international comparisons, because survival for all morphologies combined 325 
may be influenced by a higher proportion of tumours with a more favourable 326 
outcome.  327 
 328 
The results also confirm that survival is higher for type I epithelial, germ cell and sex 329 
cord-stromal tumours than for the more aggressive type II epithelial tumours. 330 
Survival from tumours with a non-specific morphology is also much lower than for 331 
tumours in any of these specific morphology groups. We would expect survival from 332 
tumours of non-specific morphology to be even lower than that of type II tumours, 333 
because most women diagnosed with ovarian cancer for whom a specific 334 
morphology is not recorded are likely to have been too sick to undergo surgery, 335 
which is required for pathological examination and morphological classification of the 336 
tumour. However, tumours recorded as unknown morphology or non-specific 337 
morphology, may be recorded as such due to lack of or incomplete pathological 338 
information reported to registries. 339 
 340 
Survival for localised tumours was much higher than for either advanced tumours or 341 
tumours of unknown stage. Early diagnosis of ovarian cancer is thus pathologically 342 
important. The result for tumours of unknown stage is not surprising, because 343 
accurate staging can only be achieved if a woman has undergone surgery. Women 344 
with significantly advanced disease are less likely to have surgery and are therefore 345 
less likely to be staged appropriately at diagnosis. Furthermore, women with higher 346 
comorbidity, some of whom will also have advanced-stage disease, may not be 347 
healthy enough for surgery and may also not have their tumours staged 348 
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appropriately.  349 
 350 
In some countries, however, survival from tumours of unknown stage was higher 351 
than that for advanced-stage tumours. In these countries, it seems more likely that 352 
unknown stage at diagnosis may be due to lack of reporting stage to registries or 353 
incomplete staging at diagnosis.  354 
 355 
Some cancer registries do not routinely collect data on tumour grade, and no 356 
information on grade was available for this study. Therefore, some serous tumours 357 
may have been misclassified, because grade is required to classify these tumours 358 
appropriately. Only high-grade serous tumours are considered as type II epithelial, 359 
but we included all serous tumours in our definition of type II epithelial, because 360 
grade was not available. We feel confident that the effect on survival is small, 361 
because only a small proportion (5%) of serous tumours are of low grade(14).  362 
 363 
We have classified all endometrioid tumours as type I epithelial, despite this subtype 364 
being previously sub-divided into type I and type II epithelial tumours(4). If grade had 365 
been available, only low-grade endometrioid tumours would have been classified as 366 
type I epithelial while high-grade endometrioid tumours should have been classified 367 
as type II epithelial based on previous definitions of type I and type II epithelial 368 
tumours(4). As with low-grade serous tumours, however, high-grade endometrioid 369 
tumours are rare, so the inclusion of these tumours in the type I epithelial group 370 
should not greatly affect the survival estimate by morphological group(14). An update 371 
in 2016 to the classification of endometrioid tumours into type I and type II epithelial 372 
tumours now classifies all endometrioid tumours as type I regardless, of tumour 373 
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grade(15). A sensitivity analysis was conducted to determine how the survival 374 
estimates varied between the two possible classifications for endometrioid tumours. 375 
Survival for both type I and type II epithelial increased when endometrioid tumours 376 
were included in each group separately. Because survival from endometrioid 377 
tumours was generally high when examined separately, we feel confident that 378 
including these tumours with the less-aggressive type I epithelial subtypes is 379 
preferable.  380 
 381 
Tumour stage is not routinely collected by cancer all registries; therefore, the 382 
analysis by stage at diagnosis could only include data from 25 countries. 383 
Additionally, changes in coding of stage at diagnosis in the US (72.7% of women 384 
included in the analysis) from the Summary Staging Guide 1977 to SEER Summary 385 
Stage 2000 meant that only data from 2001 forward could be included from the US.  386 
 387 
The quality and comparability of morphology data between countries may be limited 388 
due to differences in diagnostic techniques, morphological classification and transfer 389 
of data to the cancer registry. Almost all tumours submitted by Sweden were type II 390 
epithelial, the majority of which were unspecific epithelial carcinomas. Given that 391 
previous studies show a wider distribution of morphological subtypes(16), it is 392 
unlikely that almost all tumours from Sweden included in our analysis would have 393 
been true type II epithelial tumours. Additionally, Hong Kong only submitted epithelial 394 
ovarian cancers when submitting data for the CONCORD-2 study. Therefore, the 395 
survival comparison is limited to type I and type II epithelial tumours for Hong Kong.  396 
 397 
Our analysis was limited to tumours that had been reported by the registry as 398 
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morphologically verified, though we also included tumours with specific ICD-O-3 399 
morphology codes regardless of the reported basis of diagnosis. Morphological 400 
verification requires a tumour biopsy, thus, may not be performed if the woman 401 
presents with advanced-stage disease and is older or has a high number of 402 
comorbidities. Additionally, morphological verification may be difficult in low resource 403 
settings, where survival may be lower. Therefore, limiting our analysis to 404 
morphologically verified tumours may overestimate survival. However, given that 405 
92.7% of tumours were morphologically verified, the bias would be small.  406 
 407 
Data on treatment are not routinely collected by all cancer registries, and the 408 
registries included in the CONCORD programme were not asked to submit data on 409 
treatment. Therefore, we were unable to evaluate the impact of treatment, or lack 410 
thereof, on survival estimates for each morphological group or stage at diagnosis.  411 
 412 
The method of follow-up for obtaining the vital status of registered patients varied 413 
between cancer registries. Around 60% of registries reported using only passive 414 
follow-up, 2% reported only using active follow-up and 38% reported using both 415 
methods. The majority of patients were followed until death or at least five years after 416 
diagnosis. The data for this analysis come from the main CONCORD-2 data 417 
(n=779,302), in which only 0.6% of women were lost to follow-up and only 0.6% were 418 
censored, or diagnosed from 1995-2004 and a vital status of “alive”, but with less 419 
than five years of follow-up(1).  420 
 421 
This is the largest international population-based study of survival for ovarian cancer 422 
by morphological subtype and stage at diagnosis. The large number of women 423 
19 
 
included allowed for comparison of survival from epithelial and non-epithelial 424 
tumours, which are usually studied separately, complicating comparisons of survival 425 
between populations or over time. The differences in survival between the 426 
morphological groups emphasise the need to focus future international comparisons 427 
of ovarian cancer survival on the various subtypes, rather than analysing ovarian 428 
cancer as a single homogenous group. The results from this analysis also 429 
emphasise the need for further development of high-quality population-based cancer 430 
registries in low-income countries, and the continued improvement of the quality and 431 
completeness of cancer registry data in all countries.  432 
 433 
Word count: 3984  434 
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List of tables 710 
Table 1. Ovarian cancer morphological groups and subtypesa 711 
a No information on grade was available, therefore all endometrioid tumours were 712 
classified as type I epithelial. 713 
b No information on grade was available, therefore all serous tumours were classified 714 
as type II epithelial 715 
c Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) 716 
were excluded from the analysis of distribution of morphological subtypes (see text). 717 
 718 
Table 2. Worldwide distribution of morphology and mean age at diagnosis, 1995-719 
2009 720 
a Standard deviation.  721 
b No information on grade was available, therefore all endometrioid tumours were 722 
classified as type I epithelial.  723 
c No information on grade was available, therefore all serous tumours were classified 724 
as type II epithelial. 725 
 726 
Supplementary Table 1. Five-year age-standardised net survival (95% CI) by 727 
countrya, period of diagnosis and morphological groupb 728 
 729 
Italics denote net survival estimates that are not age-standardised.  730 
Where two or more calendar periods of diagnosis were merged, the net survival estimates 731 
are underlined.  732 
a Countries with fewer than 10 women for any morphological group (all calendar periods 733 
combined) were not included in the analysis. 734 
b Only microscopically verified tumours or tumours with a clinical diagnosis but speific 735 
mophology code are included.  736 
c Endometrioid tumours are defined as type I epithelial.   737 
d Serous tumours are defined as type II epithelial. 738 
e Number of patients included in the analysis for a given calendar period. The number of 739 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of 740 
borderline tumours and updates from registries. The number of patients in each time period 741 
may differ from Table 4 due to merging of calendar periods.   742 
 743 
 744 
Supplementary Table 2. Five-year age-standardised net survival (95% CI) by 745 
countrya, period of diagnosis for all tumours, tumours of known morphologyb and 746 
tumours of unknown morphologyb 747 
 748 
 749 
Italics denote net survival estimates that are not age-standardised.  750 
Where two or more calendar periods of diagnosis were merged, the net survival estimates 751 
are underlined.  752 
a Countries with fewer than 10 women for any morphological group (all calendar periods 753 
combined) were not included in the analysis. 754 
b Only microscopically verified tumours or tumours with a clinical diagnosis but speific 755 
mophology code are included.  756 
c Number of patients included in the analysis for a given calendar period. The number of 757 
women per registry may differ from the main CONCORD-2 analysis due to the exclusion of 758 
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borderline tumours and updates from registries. The number of patients in each time period 759 
may differ from Table 3 due to merging of calendar periods.   760 
 761 
 762 
Supplementary Table 3. Five-year age-standardised net survival (95% CI) by 763 
continent, country, registrya calendar period and stage at diagnosis 764 
 765 
Italics denote net survival estimates that are not age-standardised.  766 
Where two or more calendar periods of diagnosis were merged, the net survival estimates 767 
are underlined.  768 
a Registries with fewer than 10 women for any stage (all calendar period combined) were not 769 
included in the analysis.  770 
b Number of patients included in analysis for a given calendar period. The number of women 771 
per registry may differ from the main CONCORD-2 analysis due to the exclusion of 772 
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calendar period may not equal the sum of the number per registry for that period due to 774 
merging of calendar periods to produce the registry level estimates.  775 
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Figure 1. 5-year age-standardised net survival for Type 1 and Type 2 epithelial 779 
ovarian tumours by country, 2005-2009 780 
*Data with 100% coverage of the national population.  781 
ˠ Estimate not age-standardised.  782 
ˢ Data for two or more calendar periods of diagnosis have been merged.  783 
95% CI represented by error bars. Ranked from highest to lowest net survival by 784 
continent for women diagnosed in the calendar period of 2005-2009. 785 
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Figure 2. 5-year age-standardised net survival for germ cell, sex cord-stromal and 787 
other specific non-epithelial ovarian tumours by country, 2005-2009 788 
*Data with 100% coverage of the national population.  789 
ˠ Estimate not age-standardised. 790 
 ˢ Data for two or more calendar periods of diagnosis have been merged.  791 
95% CI represented by error bars. Ranked from highest to lowest net survival by 792 
continent for women diagnosed in the calendar period of 2005-2009. 793 
Figure 3.  5-year age-standardised net survival for localised-stage and advanced-794 
stage ovarian tumours by country, 2004-2009 795 
ˠ Estimate not age-standardised. 796 
 ˢ Data for 2001-2003 and 2004-2009 have been merged.  797 
95% CI represented by error bars.  798 
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